Frequency of disease-associated and other nuclear autoantibodies in patients of the German network for systemic scleroderma: correlation with characteristic clinical features

Arthritis Research & Therapy

Rudolf Mierau¹²  Pia Moinzadeh⁹  Gabriela Riemekasten³  Inga Melchers¹¹  Michael Meurer⁸  Frank Reichenberger⁷  Michael Buslau²  Margitta Worm²⁰  Norbert Blank¹⁹  Rüdiger Hein¹⁷  Ulf Müller-Ladner¹⁰  Annegret Kuhn⁵  Cord Sunderkötter⁵  Aaron Juche²²  Christiane Pfeiffer¹  Christoph Fiehn¹⁵  Michael Sticherling¹⁴  Percy Lehmann¹³  Rudolf Stadler¹⁶  Eckhard Schulze-Lohoff²¹  Cornelia Seitz⁴  Ivan Foeldvari⁶  Thomas Krieg⁹  Ekkehard Genth¹⁸  Nicolas Hunzelmann⁹ 

[1] Department of Dermatology and Allergology, University of Ulm, Maienweg 12, Ulm, D-89081, Germany

[2] Reha-Rheinfelden, Salinenstrasse 98, Rheinfelden, CH-4310, Switzerland

[3] Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin, Humboldt University, Charitéplatz 1, Berlin, D-10117, Germany

[4] Department of Dermatology, Venerology and Allergology, University of Würzburg, Josef-Schneider-Strasse 2, Würzburg, D-97080, Germany; present address: Department of Dermatology, Venerology and Allergology, Georg-August-University, Von-Siebold-Strasse 3, Göttingen, D-37075, Germany

[5] Department of Dermatology, University of Münster, Von-Esmarch-Strasse 58, Münster, D-48149, Germany

[6] Hamburg Centre for Pediatric and Adolescence Rheumatology, Dehnhaide 120, Hamburg Eilbek, D-22081, Germany

[7] Department of Internal Medicine II, University of Giessen, Klinikstrasse 33, Giessen, D-35392, Germany

[8] Department of Dermatology, Dresden University Hospital, Fetscherstrasse 74, Dresden, D-01307, Germany

[9] Department of Dermatology and Venerology, University of Cologne, Kerpener Strasse 62, Cologne, D-50937, Germany

[10] Department of Rheumatology and Clinical Immunology, Kerckhoff Clinic, Justus-Liebig University, Benekestrasse 2, Bad Nauheim, D-61231, Germany

[11] Clinical Research Unit for Rheumatology, University Medical Center Freiburg, Breisacher Strasse 66, Freiburg, D-79106, Germany

[12] Laboratory at Rheumaklinik Aachen, Hauptstrasse 21, Aachen, D-52066, Germany

[13] Department of Dermatology and Allergology, Helios Klinikum, Heusnerstrasse 40, Wuppertal, D-42283, Germany

[14] Department of Dermatology, Venerology and Allergology, University of Leipzig, Philipp-Rosenthal-Strasse 23, Leipzig, 04103, Germany; present address: Department of Dermatology, University Hospital Erlangen, Ulmenweg 18, Erlangen, D-91054, Germany

[15] Center for Rheumatology, Acura Hospital, Rotenbachtalstrasse 5, Baden-Baden, D-76530, Germany

[16] Department of Dermatology, Johannes-Wesling-Klinik, Hans-Nolte-Strasse 1, Minden, D-32429, Germany

[17] Department of Dermatology and Allergology, Technical University of Munich, Biedersteiner Strasse 29, Munich, D-80802, Germany

[18] Rheumaklinik Aachen, Burtscheider Markt 24, Aachen, D-52066, Germany

[19] Department of Internal Medicine V, University of Heidelberg, Im Neuenheimer Feld 410, Heidelberg, D-69120, Germany

[20] Department of Dermatology, Venerology and Allergology, Charité Universitätsmedizin, Humboldt University, Charitéplatz 1, Berlin, D-10117, Germany

[21] Medical Clinic I, Hospital Cologne-Merheim, Ostmerheimer Strasse 200, Cologne, D-51109, Germany; present address: Medical Clinic 6, Marien-Hospital, Wanheimer Strasse 167a, Duisburg, D-47053, Germany

[22] Center of Rheumatology of Brandenburg, Johanniter Hospital in Fläming, Johanniterstrasse 1, Treuenbrietzen, D-14929, Germany

关键词: antinuclear antibodies;    autoantibodies;    scleroderma;    systemic sclerosis;   

Others  :  1098465
DOI  :  10.1186/ar3495

 received in 2011-07-21, accepted in 2011-10-21,  发布年份 2011

【 摘 要 】

Introduction

In the present study, we analysed in detail nuclear autoantibodies and their associations in systemic sclerosis (SSc) patients included in the German Network for Systemic Scleroderma Registry.

Methods

Sera of 863 patients were analysed according to a standardised protocol including immunofluorescence, immunoprecipitation, line immunoassay and immunodiffusion.

Results

Antinuclear antibodies (ANA) were detected in 94.2% of patients. In 81.6%, at least one of the autoantibodies highly associated with SSc or with overlap syndromes with scleroderma features was detected, that is, anti-centromere (35.9%) or anti-topoisomerase I (30.1%), followed in markedly lower frequency by antibodies to PM-Scl (4.9%), U1-ribonucleoprotein (U1-RNP) (4.8%), RNA polymerases (RNAPs) (3.8%), fibrillarin (1.4%), Ku (1.2%), aminoacyl-transfer RNA synthetases (0.5%), To (0.2%) and U11-RNP (0.1%). We found that the simultaneous presence of SSc-associated autoantibodies was rare (1.6%). Furthermore, additional autoantibodies were detected in 55.4% of the patients with SSc, of which anti-Ro/anti-La, anti-mitochondrial and anti-p25/p23 antibodies were most frequent. The coexistence of SSc-associated and other autoantibodies was common (43% of patients). SSc-associated autoantibodies disclosed characteristic associations with clinical features of patients, some of which were previously not acknowledged.

Conclusions

This study shows that five autoantigens (that is, centromere, topoisomerase I, PM-Scl, U1-RNP and RNAP) detected more than 95% of the known SSc-associated antibody responses in ANA-positive SSc patients and characterise around 79% of all SSc patients in a central European cohort. These data confirm and extend previous data underlining the central role of the determination of ANAs in defining the diagnosis, subset allocation and prognosis of SSc patients.

【 授权许可】

   
2011 Mierau et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Cepeda EJ, Reveille JD: Autoantibodies in systemic sclerosis and fibrosing syndromes: clinical indications and relevance. Curr Opin Rheumatol 2004, 16:723-732.
• [2]Steen VD: Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005, 35:35-42.
• [3]Walker JG, Fritzler MJ: Update on autoantibodies in systemic sclerosis. Curr Opin Rheumatol 2007, 19:580-591.
• [4]Masi AT, Rodnan GP, Medsger TA Jr, Altman RD, D'Angelo WAD, Fries JF, LeRoy EC, Kirsner AB, MacKenzie AH, McShane DJ, Myers AR, Sharp GC, the Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980, 23:581-590.
• [5]LeRoy EC, Medsger TA Jr: Criteria for the classification of early systemic sclerosis. J Rheumatol 2001, 28:1573-1576.
• [6]Koenig M, Joyal F, Fritzler MJ, Roussin A, Abrahamowicz M, Boire G, Goulet JR, Rich É, Grodzicky T, Raymond Y, Senécal JL: Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 2008, 58:3902-3912.
• [7]Elicha Gussin HA, Ignat GP, Varga J, Teodorescu M: Anti-topoisomerase I (anti-Scl-70) antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 2001, 44:376-383.
• [8]Steen VD, Powell DL, Medsger TA Jr: Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988, 31:196-203.
• [9]Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G, Bullo A, Cazzato M, Tirri E, Storino F, Giuggioli D, Cuomo G, Rosada M, Bombardieri S, Todesco S, Tirri G: Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine 2002, 81:139-153.
• [10]Scussel-Lonzetti L, Joyal F, Raynauld JP, Roussin A, Rich É, Goulet JR, Raymond Y, Senécal JL: Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore) 2002, 81:154-167.
• [11]Mayes MD, Lacey JV Jr, Beebe-Dimmer J, Gillespie BW, Cooper B, Laing TJ, Schottenfeld D: Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003, 48:2246-2255.
• [12]Walker UA, Tyndall A, Czirják L, Denton C, Farge-Bancel D, Kowal-Bielecka O, Müller-Ladner U, Bocelli-Tyndall C, Matucci-Cerinic M, EUSTAR: Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007, 66:754-763.
• [13]Arnett FC, Reveille JD, Goldstein R, Pollard KM, Leaird K, Smith EA, LeRoy EC, Fritzler MJ: Autoantibodies to fibrillarin in systemic sclerosis (scleroderma): an immunogenetic, serologic, and clinical analysis. Arthritis Rheum 1996, 39:1151-1160.
• [14]Bunn CC, Denton CP, Shi-Wen X, Knight C, Black CM: Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis. Br J Rheumatol 1998, 37:15-20.
• [15]Jacobsen S, Halberg P, Ullman S, van Venrooij WJ, Høier-Madsen M, Wiik A, Petersen J: Clinical features and serum antinuclear antibodies in 230 Danish patients with systemic sclerosis. Br J Rheumatol 1998, 37:39-45.
• [16]Hesselstrand R, Scheja A, Shen GQ, Wiik A, Akesson A: The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis. Rheumatology (Oxford) 2003, 42:534-540.
• [17]Rozman B, Cucnik S, Sodin-Semrl S, Czirják L, Varjú C, Distler O, Huscher D, Aringer M, Steiner G, Matucci-Cerinic M, Guiducci S, Stamenkovic B, Stankovic A, Kveder T: Prevalence and clinical associations of anti-Ku antibodies in patients with systemic sclerosis: a European EUSTAR-initiated multi-centre case-control study. Ann Rheum Dis 2008, 67:1282-1286.
• [18]Hunzelmann N, Genth E, Krieg T, Lehmacher W, Melchers I, Meurer M, Moinzadeh P, Müller-Ladner U, Pfeiffer C, Riemekasten G, Schulze-Lohoff E, Sunderkötter C, Weber M, Worm M, Klaus P, Rubbert A, Steinbrink K, Grundt B, Hein R, Scharffetter-Kochanek K, Hinrichs R, Walker K, Szeimies RM, Karrer S, Müller A, Seitz C, Schmidt E, Lehmann P, Foeldvári I, Reichenberger F, Registry of the German Network for Systemic Scleroderma, et al.: The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology (Oxford) 2008, 47:1185-1192.
• [19]Hunzelmann N, Moinzadeh P, Genth E, Krieg T, Lehmacher W, Melchers I, Meurer M, Müller-Ladner U, Olski TM, Pfeiffer C, Riemekasten G, Schulze-Lohoff E, Sunderkötter C, Weber M, German Network for Systemic Scleroderma Centers: High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy. Arthritis Res Ther 2009, 11:R30.
• [20]LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, Rowell N, Wollheim F: Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988, 15:202-205.
• [21]Bennett RM: Scleroderma overlap syndromes. Rheum Dis Clin North Am 1990, 16:185-198.
• [22]Pope JE: Scleroderma overlap syndromes. Curr Opin Rheumatol 2002, 14:704-710.
• [23]Poormoghim H, Lucas M, Fertig N, Medsger TA Jr: Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients. Arthritis Rheum 2000, 43:444-451.
• [24]Giordano M, Valentini G, Migliaresi S, Picillo U, Vatti M: Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis. J Rheumatol 1986, 13:911-916.
• [25]Alarcón GS: Unclassified or undifferentiated connective tissue disease. Baillieres Best Pract Res Clin Rheumatol 2000, 14:125-137.
• [26]LeRoy EC, Maricq HR, Kahaleh MB: Undifferentiated connective tissue syndromes. Arthritis Rheum 1980, 23:341-343.
• [27]Sack U, Conrad K, Csernok E, Frank I, Hiepe F, Krieger T, Kromminga A, von Landenberg P, Messer G, Witte T, Mierau R, German EASI (European Autoimmunity Standardization Initiative): Autoantibody detection using indirect immunofluorescence on HEp-2 cells. Ann N Y Acad Sci 2009, 1173:166-173.
• [28]Harvey GR, Black CM, Maddison PJ, McHugh NJ: Characterization of antinucleolar antibody reactivity in patients with systemic sclerosis and their relatives. J Rheumatol 1997, 24:477-484.
• [29]Hirakata M, Suwa A, Takada T, Sato S, Nagai S, Genth E, Song YW, Mimori T, Targoff IN: Clinical and immunogenetic features of patients with autoantibodies to asparaginyl-transfer RNA synthetase. Arthritis Rheum 2007, 56:1295-1303.
• [30]Muro Y, Yamada T, Iwai T, Sugimoto K: Epitope analysis of chromo antigen and clinical features in a subset of patients with anti-centromere antibodies. Mol Biol Rep 1996, 23:147-151.
• [31]Iwai T, Muro Y, Sugimoto K, Matsumoto Y, Ohashi M: Clinical features of anti-chromo antibodies associated with anti-centromere antibodies. Clin Exp Immunol 1996, 105:285-290.
• [32]Genth E, Mierau R, Genetzky P, von Mühlen CA, Kaufmann S, von Wilmowsky H, Meurer M, Krieg T, Pollmann HJ, Hartl PW: Immunogenetic associations of scleroderma-related antinuclear antibodies. Arthritis Rheum 1990, 33:657-665.
• [33]Meyer OC, Fertig N, Lucas M, Somogyi N, Medsger TA Jr: Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis. J Rheumatol 2007, 34:104-109.
• [34]Hamaguchi Y, Hasegawa M, Fujimoto M, Matsushita T, Komura K, Kaji K, Kondo M, Nishijima C, Hayakawa I, Ogawa F, Kuwana M, Takehara K, Sato S: The clinical relevance of serum antinuclear antibodies in Japanese patients with systemic sclerosis. Brit J Dermatol 2008, 158:487-495.
• [35]Fanning GC, Welsh KI, Bunn C, du Bois RM, Black CM: HLA associations in three mutually exclusive autoantibody subgroups in UK systemic sclerosis patients. Br J Rheumatol 1998, 37:201-207.
• [36]Kuwana M, Kaburaki J, Okano Y, Tojo T, Homma M: Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 1994, 37:75-83.
• [37]Dick T, Mierau R, Bartz-Bazzanella P, Alavi M, Stoyanova-Scholz M, Kindler J, Genth E: Coexistence of anti-topoisomerase 1 and anti-centromere antibodies in patients with systemic sclerosis. Ann Rheum Dis 2002, 61:121-127.
• [38]Hanke K, Becker MO, Brueckner CS, Meyer W, Janssen A, Schlumberger W, Hiepe F, Burmester GR, Riemekasten G: Anticentromere-A and anticentromere-B antibodies show high concordance and similar clinical associations in patients with systemic sclerosis. J Rheumatol 2010, 37:2548-2552.
• [39]Gliddon AE, Dore CJ, Dunphy J, Betteridge Z, McHugh NJ, Maddison PJ: Antinuclear antibodies and clinical associations in a British cohort with limited cutaneous systemic sclerosis. J Rheumatol 2011, 38:702-705.
• [40]Falkner D, Wilson J, Fertig N, Clawson K, Medsger TA Jr, Morel PA: Studies of HLA-DR and DQ alleles in systemic sclerosis patients with autoantibodies to RNA polymerases and U3-RNP (fibrillarin). J Rheumatol 2000, 27:1196-1202.
• [41]Tiev KP, Diot E, Clerson P, Dupuis-Siméon F, Hachulla E, Hatron PY, Constans J, Cirstéa D, Farge-Bancel D, Carpentier PH: Clinical features of scleroderma patients with or without prior or current ischemic digital ulcers: post-hoc analysis of a nationwide multicenter cohort (ItinérAIR-Sclérodermie). J Rheumatol 2009, 36:1470-1476.
• [42]Sunderkötter C, Herrgott I, Brückner C, Moinzadeh P, Pfeiffer C, Gerss J, Hunzelmann N, Böhm M, Krieg T, Müller-Ladner U, Genth E, Schulze-Lohoff E, Meurer M, Melchers I, Riemekasten G, DNSS Centers: Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors. Brit J Dermatol 2009, 160:835-843.
• [43]Khimdas S, Harding S, Bonner A, Zummer B, Baron M, Pope J, Canadian Scleroderma Research Group: Associations with digital ulcers in a large cohort of systemic sclerosis: results from the Canadian Scleroderma Research Group registry. Arthritis Care Res 2011, 63:142-149.
• [44]Akiyama Y, Tanaka M, Takeishi M, Adachi D, Mimori A, Suzuki T: Clinical, serological and genetic study in patients with CREST syndrome. Intern Med 2000, 39:451-456.
• [45]Miyawaki S, Asanuma H, Nishiyama S, Yoshinaga Y: Clinical and serological heterogeneity in patients with anticentromere antibodies. J Rheumatol 2005, 32:1488-1494.
• [46]Picha L, Pakas I, Guialis A, Moutsopoulos HM, Vlachoyiannopoulos PG: Comparative qualitative and quantitative analysis of scleroderma (systemic sclerosis) serologic immunoassays. J Autoimmun 2008, 31:166-174.
• [47]Marasini B, Gagetta M, Rossi V, Ferrari P: Rheumatic disorders and primary biliary cirrhosis: an appraisal of 170 Italian patients. Ann Rheum Dis 2001, 60:1046-1049.
• [48]Rigamonti C, Shand LM, Feudjo M, Bunn CC, Black CM, Denton CP, Burroughs AK: Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis. Gut 2006, 55:388-394.
• [49]Soriano E, Whyte J, McHugh NJ: Frequency and clinical associations of anti-chromo antibodies in connective tissue disease. Ann Rheum Dis 1994, 53:666-670.
• [50]Furuta K, Hildebrandt B, Matsuoka S, Kiyosawa K, Reimer G, Luderschmidt C, Chan EKL, Tan EM: Immunological characterization of heterochromatin protein p25β autoantibodies and relationship with centromere autoantibodies and pulmonary fibrosis in systemic scleroderma. J Mol Med (Berl) 1998, 76:54-60.
• [51]Hanke K, Dähnrich C, Brückner CS, Huscher D, Becker M, Jansen A, Meyer W, Egerer K, Hiepe F, Burmester GR, Schlumberger W, Riemekasten G: Diagnostic value of anti-topoisomerase I antibodies in a large monocentric cohort. Arthritis Res Ther 2009, 11:R28. BioMed Central Full Text
• [52]Nguyen B, Mayes MD, Arnett FC, Del Junco D, Reveille JD, Gonzalez EB, Draeger HT, Perry M, Hendiani A, Anand KK, Assassi S: HLA-DRB1*0407 and *1304 are risk factors for scleroderma renal crisis. Arthritis Rheum 2011, 63:530-534.
• [53]Chang MG, Wang RJ, Yangco DT, Sharp GC, Komatireddy GR, Hoffman RW: Analysis of autoantibodies against RNA polymerases using immunoaffinity-purified RNA polymerase I, II, and III antigen in an enzyme-linked immunosorbent assay. Clin Immunol Immunopathol 1998, 89:71-78.
• [54]Santiago M, Baron M, Hudson M, Burlingame RW, Fritzler MJ: Antibodies to RNA polymerase III in systemic sclerosis detected by ELISA. J Rheumatol 2007, 34:1528-1534.
• [55]Okano Y, Steen VD, Medsger TA Jr: Autoantibody reactive with RNA polymerase III in systemic sclerosis. Ann Intern Med 1993, 119:1005-1013.
• [56]Bardoni A, Rossi P, Salvini R, Bobbio-Pallavicini F, Caporali R, Montecucco C: Autoantibodies to RNA-polymerases in Italian patients with systemic sclerosis. Clin Exp Rheumatol 2003, 21:301-306.
• [57]Meyer O, De Chaisemartin L, Nicaise-Roland P, Cabane J, Tubach F, Dieude P, Hayem G, Palazzo E, Chollet-Martin S, Kahan A, Allanore Y: Anti-RNA polymerase III antibody prevalence and associated clinical manifestations in a large series of French patients with systemic sclerosis: a cross-sectional study. J Rheumatol 2010, 37:125-130.
• [58]Harvey GR, Butts S, Rands AL, Patel Y, McHugh NJ: Clinical and serological associations with anti-RNA polymerase antibodies in systemic sclerosis. Clin Exp Immunol 1999, 117:395-402.
• [59]Airo' P, Ceribelli A, Cavazzana I, Taraborelli M, Zingarelli S, Franceschini F: Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies. J Rheumatol 2011, 38:1329-1334.
• [60]Satoh T, Ishikawa O, Ihn H, Endo H, Kawaguchi Y, Sasaki T, Goto D, Takahashi K, Takahashi H, Misaki Y, Mimori T, Muro Y, Yazawa N, Sato S, Takehara K, Kuwana M: Clinical usefulness of anti-RNA polymerase III antibody measurement by enzyme-linked immunosorbent assay. Rheumatology (Oxford) 2009, 48:1570-1574.
• [61]Tormey VJ, Bunn CC, Denton CP, Black CM: Anti-fibrillarin antibodies in systemic sclerosis. Rheumatology (Oxford) 2001, 40:1157-1162.
• [62]Reveille JD, Fischbach M, McNearney T, Friedman AW, Aguilar MB, Lisse J, Fritzler MJ, Ahn C, Arnett FC: Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum 2001, 30:332-346.
• [63]Aggarwal R, Lucas M, Fertig N, Oddis CV, Medsger TA Jr: Anti-U3 RNP autoantibodies in systemic sclerosis. Arthritis Rheum 2009, 60:1112-1118.
• [64]Oddis CV, Okano Y, Rudert WA, Trucco M, Duquesnoy RJ, Medsger TA Jr: Serum autoantibody to the nucleolar antigen PM-Scl: clinical and immunogenetic associations. Arthritis Rheum 1992, 35:1211-1217.
• [65]Marguerie C, Bunn CC, Copier J, Bernstein RM, Gilroy JM, Black CM, So AK, Walport MJ: The clinical and immunogenetic features of patients with autoantibodies to the nucleolar antigen PM-Scl. Medicine (Baltimore) 1992, 71:327-336.
• [66]Vandergheynst F, Ocmant A, Sordet C, Humbel RL, Goetz J, Roufosse F, Cogan E, Sibilia J: Anti-PM/scl antibodies in connective tissue disease: clinical and biological assessment of 14 patients. Clin Exp Rheumatol 2006, 24:129-133.
• [67]Targoff IN: Humoral immunity in polymyositis/dermatomyositis. J Invest Dermatol 1993, 100:116S-123S.
• [68]Katano K, Kawano M, Koni I, Sugai S, Muro Y: Clinical and laboratory features of anticentromere antibody positive primary Sjögren's syndrome. J Rheumatol 2001, 28:2238-2244.
• [69]Osial TA Jr, Whiteside TL, Buckingham RB, Singh G, Barnes EL, Pierce JM, Rodnan GP: Clinical and serologic study of Sjögren's syndrome in patients with progressive systemic sclerosis. Arthritis Rheum 1983, 26:500-508.
• [70]Drosos AA, Andonopoulos AP, Costopoulos JS, Stavropoulos ED, Papadimitriou CS, Moutsopoulos HM: Sjögren's syndrome in progressive systemic sclerosis. J Rheumatol 1988, 15:965-968.
• [71]Kuwana M, Okano Y, Pandey JP, Silver RM, Fertig N, Medsger TA Jr: Enzyme-linked immunosorbent assay for detection of anti-RNA polymerase III antibody: analytical accuracy and clinical associations in systemic sclerosis. Arthritis Rheum 2005, 52:2425-2432.
• [72]Yamasaki Y, Honkanen-Scott M, Hernandez L, Ikeda K, Barker T, Bubb MR, Narain S, Richards HB, Chan EK, Reeves WH, Satoh M: Nucleolar staining cannot be used as a screening test for the scleroderma marker anti-RNA polymerase I/III antibodies. Arthritis Rheum 2006, 54:3051-3056.
• [73]Mahler M, Raijmakers R, Dähnrich C, Blüthner M, Fritzler MJ: Clinical evaluation of autoantibodies to a novel PM/Scl peptide antigen. Arthritis Res Ther 2005, 7:R704-R713. BioMed Central Full Text
• [74]Gilliam AC, Steitz JA: Rare scleroderma autoantibodies to the U11 small nuclear ribonucleoprotein and to the trimethylguanosine cap of U small nuclear RNAs. Proc Natl Acad Sci USA 1993, 90:6781-6785.
• [75]Feghali-Bostwick C, Medsger TA Jr, Wright TM: Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum 2003, 48:1956-1963.
• [76]Saunders WS, Chue C, Goebl M, Craig C, Clark RF, Powers JA, Eissenberg JC, Elgin SC, Rothfield NF, Earnshaw WC: Molecular cloning of a human homologue of Drosophila heterochromatin protein HP1 using anti-centromere autoantibodies with anti-chromo specificity. J Cell Sci 1993, 104:573-582.
• [77]Furuta K, Chan EK, Kiyosawa K, Reimer G, Luderschmidt C, Tan EM: Heterochromatin protein HP1Hsβ(p25β) and its localization with centromeres in mitosis. Chromosoma 1997, 106:11-19.
• [78]Dick T, Mierau R, Sternfeld R, Weiner EM, Genth E: Clinical relevance and HLA association of autoantibodies against the nucleolus organizer region (NOR-90). J Rheumatol 1995, 22:67-72.
• [79]Szostecki C, Guldner HH, Netter HJ, Will H: Isolation and characterization of cDNA encoding a human nuclear antigen predominantly recognized by autoantibodies from patients with primary biliary cirrhosis. J Immunol 1990, 145:4338-4347.